Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

about

Silencing of suppressor of cytokine signaling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment.

P2860

Q49482744-E855EFC6-3B85-4249-BCFE-173EE90ADC97

P2860

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

Item

http://www.wikidata.org/entity/Q42376411

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@en

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@nl

type

Item

label

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@en

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@nl

prefLabel

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@en

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@nl

P1476

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

@en

P2093

Chang Bai Liu

http://www.w3.org/2001/XMLSchema#string

Jun Wang

http://www.w3.org/2001/XMLSchema#string

Song Qin

http://www.w3.org/2001/XMLSchema#string

Zhi Peng Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2013

Calreticulin exposure dictates the immunogenicity of cancer cell death

Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Tolerogenic dendritic cells

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin.

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28

A mechanism of release of calreticulin from cells during apoptosis.

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

P304

3399-3406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2017.4989

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lili Zou

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29042925

http://www.w3.org/2001/XMLSchema#string

P932

5639401

http://www.w3.org/2001/XMLSchema#string

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

about

P2860

P2860

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932